In order to further examine the mechanism underlying the effects of selective TXS inhibition, RT2 ProfilerTM Cancer PathwayFinder PCR arrays were used to examine the expression of a panel of genes implicated in tumourigenesis following 24 h treatment with ozagrel (additional file 1). This evidence concerns the gene TBXAS1 and cancer.